



TREAT TO  
TARGET  
IN IBD:  
Lights and  
Shadows

preliminary  
program

Lido di Camaiore (LU)  
10-11 November 2016

## RATIONALE

Inflammatory bowel diseases (IBD) are chronic, progressive, and disabling conditions. Most current strategies, which target control of symptoms, do not appear to significantly alter the natural course of the disease. Recent studies underscore the need to look beyond symptoms and to treat endoscopic/macroscopic lesions in both CD and UC with the final aim of preventing structural damage and disability. A “treat-to-target” strategy has been advocated as an optimized management approach for different condition such as rheumatoid arthritis, diabetes mellitus and hypertension. In this approach targets have been defined to improve outcomes and reduce the risk of end-organ damage (such as joint damage in rheumatoid arthritis and macrovascular or microvascular complications in diabetes mellitus. The objective of this congress is to focus the limitations of the traditional management of IBD and to define potential treat-to-target strategies that could be used in routine clinical practice.

## RESPONSABILE SCIENTIFICO

Fernando Rizzello

## COMITATO EDUCAZIONALE IG-IBD

Marco Daperno

Claudio Papi

## BOARD SCIENTIFICO

Alessandro Armuzzi

Marco Daperno

## FACULTY

Vito Annese

Sandro Ardizzone

Alessandro Armuzzi

Livia Biancone

Corrado Blandizzi

Giorgia Bodini

Carlo Calabrese

Emma Calabrese

Fabrizio Cantini

Flavio Caprioli

Fabiana Castiglione

Michele Comberlato

Francesco Costa

Silvio Danese

Marco Daperno

Renata D’Inca

Massimo Fantini

Gionata Fiorino

Paolo Gionchetti

Anna Kohn

Giovanni Maconi

Gianmichele Meucci

Filippo Mocciaro

Alberto Morganti

Ambrogio Orlando

Claudio Papi

Dario Pitocco

Mariabeatrice Principi

Daniela Pugliese

Fernando Rizzello

Simone Saibeni

Edoardo Savarino

Gian Eugenio Tontini

Maurizio Vecchi

Vincenzo Villanacci

# PRELIMINARY PROGRAM

**Thursday, November 10<sup>th</sup>**

12.00 - 13.00 *Welcome lunch*

## **SESSION 1: The concept of treat to target**

*Chairmen: A. Armuzzi, M. Vecchi*

13.00 - 13.20 Why symptomatic control is not enough in IBD?  
*C. Papi*

13.20 - 13.40 Treat-to-target in Diabetes: rationale and strategies  
*D. Pitocco*

13.40 - 14.00 Treat-to-target in Cardiovascular diseases: rationale and strategies  
*A. Morganti*

14.00 - 14.20 Treat-to-target in Rheumatic diseases: rationale and strategies  
*F. Cantini*

14.20 - 14.40 Round Table and discussion  
*F. Cantini, A. Morganti, C. Papi, D. Pitocco*

## **SESSION 2: Conventional and tailored approach to ulcerative colitis management in the era of treat-to-target**

*Chairmen: S. Ardizzone, A. Kohn*

14.40 - 15.00 Ulcerative colitis: which are the best treat-to-target managing strategies?  
*D. Pugliese*

15.00 - 15.20 When ulcerative colitis is in remission: how to tailor surveillance?  
*G.E. Tontini*

15.20 - 15.40 Histology in ulcerative colitis: is it the ultimate target?  
*V. Villanacci*

15.40 - 16.00 Round Table and discussion  
*D. Pugliese, G.E. Tontini, V. Villanacci*

16.00 - 16.30 **EXTRA CME SESSION**  
Adalimumab: safe & systemic control for IBD  
*A. Armuzzi, C. Blandizzi*

16.30 - 17.00 **Coffee break**

### **SESSION 3: Conventional and tailored approach to Crohn's disease management in the era of treat-to-target**

*Chairmen: M. Fantini, F. Rizzello*

17.00 - 17.20 Luminal Crohn's disease: which are the best treat-to-target managing strategies?  
*F. Caprioli*

17.20 - 17.40 Perianal Crohn's disease: which are the best treat-to-target managing strategies?  
*P. Gionchetti*

17.40 - 18.00 Postoperative Crohn's disease: which are the best treat-to-target managing strategies?  
*E. Savarino*

18.00 - 18.30 Round Table and discussion  
*F. Caprioli, P. Gionchetti, E. Savarino*

### **SESSION 4: Therapeutic drug monitoring (TDM) in IBD: where are we and where are we heading to?**

*Chairmen: F. Costa, A. Orlando*

18.30 - 19.00 Face to face - Thiopurines: clinical or TDM approach?  
*G. Meucci, S. Saibeni*

19.00 - 19.30 Face-to-face - AntiTNF and newer biologic treatment: clinical or TDM approach?  
*G. Bodini, B. Principi*

19.30 - 19.50 Round Table and discussion  
*G. Bodini, G. Meucci, B. Principi, S. Saibeni*

# Friday, November 11<sup>th</sup>

## SESSION 5: How to assess the bowel: endoscopy and stool tests for treat-to-target

Chairmen: V. Annese, L. Biancone

- 08.30 - 08.50 Endoscopy and endoscopic healing: a lesson from ulcerative colitis  
*F. Mocciaro*
- 08.50 - 09.10 Endoscopy and endoscopic healing: a lesson from Crohn's disease  
*M. Comberlato*
- 09.10 - 09.30 How reliable can be endoscopic scoring for IBD?  
*M. Daperno*
- 09.30 - 09.50 Stool tests: any advantage for clinical practice?  
*R. D'Incà*
- 09.50 - 10.10 Round Table and discussion  
*M. Comberlato, M. Daperno, R. D'Incà, F. Mocciaro*
- 10.10 - 10.40 **EXTRA CME SESSION**  
Vedolizumab: real world experience  
*M. Daperno*
- 10.40 - 11.10 **Coffee break**
- 11.10 - 11.40 **EXTRA CME SESSION**  
New perspectives in Ulcerative Colitis management  
*Chairman: M. Vecchi*
- 11.10 - 11.25 Treat to target and patient's tight control: emerging targets in ulcerative colitis management  
*S. Danese*
- 11.25 - 11.40 The value of CCR in patient's management: from clinical trial to Real Life evidence  
*A. Armuzzi*

## SESSION 6: Reaching the target where the eye cannot dare

Chairmen: *F. Castiglione, G. Maconi*

- 11.40 - 12.00 Can US tell us something on small bowel?  
*E. Calabrese*
- 12.00 - 12.20 Can MRI/CT tell us something on small bowel?  
*G. Fiorino*
- 12.20 - 12.40 Can capsule endoscopy tell us something on small bowel?  
*C. Calabrese*
- 12.40 - 13.00 What are STRIDE commitments and how to integrate them in clinical practice?  
*S. Danese*
- 13.00 - 13.20 Round Table and discussion  
*C. Calabrese, E. Calabrese, S. Danese, G. Fiorino*
- 13.20 - 13.40 **CME completion**
- 13.40 - 14.30 **Lunch**
- 14.30 - 16.30 IG-IBD partner's meeting

## SEDE del CORSO

UNA Hotel Versilia

Viale S. Bernardini 335/337 - 55041 Lido di Camaiore (LU)

## QUOTA di ISCRIZIONE € 366,00 (Iva 22% inclusa)

L'iscrizione comprende la partecipazione ai lavori scientifici, i servizi ristorativi (coffee break e lunch come da programma) e la partecipazione alla cena sociale di giovedì 10 novembre.

## ACCREDITAMENTO ECM

L'evento è stato accreditato dal Provider PLS Educational (3516-165949 Ed. 1) per la professione del Medico Chirurgo nelle discipline di Gastroenterologia, Medicina Interna, e Chirurgia Generale.

L'evento prevede l'assegnazione di 6,8 crediti formativi.

## PROVIDER ECM e SEGRETERIA ORGANIZZATIVA



**PLS Educational Srl**

Via della Mattonaia, 17 - 50121 Firenze

Tel: 055.24621 - Fax: 055.2462270

Email: [ig-ibd@promoleader.com](mailto:ig-ibd@promoleader.com)

L'evento è realizzato con il contributo non condizionato di:

abbvie



[www.ig-ibd.com](http://www.ig-ibd.com)